Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: ERN, CCA

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update


Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients

Joined the global effort against COVID-19 with plonmarlimab (TJM2) study which represents the first double-blind, placebo-controlled study evaluating anti-GM-CSF antibody in severe COVID-19 patients    

The Company expects significant pipeline updates in H2 2020 including China registrational trial with CD38 antibody felzartamab (TJ202) as third-line monotherapy for multiple myeloma; the Company also expects IND approval for eftansomatropin (TJ101), a unique long acting growth hormone in the fourth quarter of 2020 and to initiate phase 3 study subsequently

The Company to host conference call and webcast on August 31 at 8:00 a.m. ET

SHANGHAI and GAITHERSBURG, Md., Aug. 31, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced financial results for the six months ended June 30, 2020 and provided an overview of recent highlights and upcoming milestones.

"I-Mab continues to advance our robust pipeline, create value through innovation, and is well positioned to become a fully integrated global biopharmaceutical company. The differentiation of our innovative assets has become validated as the clinical trials progress, as exemplified by our positive preliminary clinical results for lemzoparlimab," said Dr. Jingwu Zang, Founder, Honorary Chairman and Director of I-Mab. "Looking ahead, we remain excited and confident in our science and increasing capabilities to deliver the promised corporate and pipeline development milestones and create value for patients as well as for our shareholders."

The Company expects multiple data readouts across a progressing pipeline in the coming months. These include the clinical results of phase 1 clinical trial in the U.S. and China for lemzoparlimab, initial data from uliledlimab (TJD5), the differentiated CD73 antibody, Part 2 clinical update from plonmarlimab in patients with cytokine release syndrome associated with severe COVID-19, as well as phase 2 results from olamkicept (TJ301) in patients with ulcerative colitis. Felzartamab (TJ202), the Company's in-licensed CD38 antibody, is being evaluated in two parallel registrational studies in China for the treatment of multiple myeloma and is on track for subject enrollment.

In addition, the Company's recent appointment of Chief Commercial Officer Ivan Yifei Zhu marks the Company's commitment to building commercial capability and executing our commercialization plans for upcoming product launches. The remarkable progress in pipeline and corporate development demonstrated during this period significantly strengthens the Company's position to achieve longer-term growth into 2021 and beyond.

Recent Highlights and Upcoming Milestones

Internally Discovered Global Pipeline

"Fast to Market" China Portfolio

Corporate

Commercialization Capability

First Half 2020 Financial Results

Cash Position

As of June 30, 2020, the Company had cash, cash equivalents, restricted cash and short-term investments of RMB1.6 billion (US$221.1 million), compared with RMB1.2 billion as of December 31, 2019.

Net Revenues

Total net revenues for the six months ended June 30, 2020 were nil, compared with RMB15.0 million for the six months ended June 30, 2019.

Research & Development Expenses

Research and development expenses for the six months ended June 30, 2020 were RMB442.3 million (US$62.6 million), compared with RMB265.1 million for the six months ended June 30, 2019. The increase was primarily due to increases in CRO service fees to advance the Company's pipelines, higher share-based compensation, and higher employee salary and benefits expenses due to increased research and development headcount.

Administrative Expenses

Administrative expenses for the six months ended June 30, 2020 were RMB171.4 million (US$24.3 million), compared with RMB574.6 million for the six months ended June 30, 2019. The decrease was primarily due to reduced share-based compensation expenses of RMB268.9 million (US$38.1 million).

Net Loss

Net loss for the six months ended June 30, 2020 was RMB582.9 million (US$82.5 million), compared with RMB857.3 million for the six months ended June 30, 2019. Net loss per share attributable to ordinary shareholders for the six months ended June 30, 2020 was RMB4.78 (US$0.68), compared with RMB119.34 for the six months ended June 30, 2019.

Non-GAAP Net Loss

Non-GAAP adjusted net loss, which excludes share-based compensation expenses, for the six months ended June 30, 2020 was RMB353.1 million (US$50.0 million), compared with RMB491.0 million for the six months ended June 30, 2019. Non-GAAP adjusted net loss per share attributable to ordinary shareholders for the six months ended June 30, 2020 was RMB2.90 (US$0.41), compared with RMB68.34 for the six months ended June 30, 2019.

Conference Call and Webcast Information

The Company will host a live conference call and webcast on August 31, 2020 at 8:00 a.m. ET. Participants must register in advance of the conference call. Details are as follows:

Registration Link:

http://apac.directeventreg.com/registration/event/8959387

Conference ID:

8959387

Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

A webcast replay will be archived on the Company's website for one year after the conclusion of the call at http://ir.i-mabbiopharma.com.

A telephone replay will be available approximately two hours after the conclusion of the call. To access the replay, please call +1-855-452-5696 (U.S.), +61-2-8199-0299 (International), 400-632-2162 (Mainland China), or 800-963-117 (Hong Kong). The conference ID number for the replay is 8959387.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com

Use of Non-GAAP Financial Measures

To supplement its consolidated financial statements which are presented in accordance with U.S. GAAP, the Company uses adjusted net loss as a non-GAAP financial measure. Adjusted net loss represents net loss before share-based compensation. The Company's management believes that adjusted net loss facilitates better understanding of operating results and provide management with a better capability to plan and forecast future periods. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

Non-GAAP information is not prepared in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using adjusted net loss is that adjusted net loss excludes share-based compensation expense that has been and may continue to be incurred in the future.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB7.0651 to US$1.00, the rate in effect as of June 30, 2020 published by the Federal Reserve Board.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to" and similar statements. Statements that are not historical facts, including statements about I-Mab's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in I-Mab's filings with the SEC. All information provided in this press release is as of the date of this press release, and I-Mab does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

I-Mab
Jielun Zhu, CFO
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Vice President and Global Head of Corporate Communications
E-mail: Gigi.Feng@i-mabbiopharma.com
Office line: +86 21 6057 8000

Investor Inquiries:
Burns McClellan, Inc. (Americas and Europe)
Steve Klass
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006

The Piacente Group, Inc. (Asia)
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

 

 

 

I-MAB

Consolidated Balance Sheets

(All amounts in thousands, except for share and per share data, unless otherwise noted)






As of December 31,


As of June 30,





2019


2020





RMB


RMB


US$ 










Assets









Current assets









   Cash and cash equivalents




1,137,473


1,560,031


220,808

Restricted cash




55,810


-


-

Short-term investments




32,000


1,926


273

Prepayments and other receivables




136,036


131,130


18,560

Total current assets




1,361,319


1,693,087


239,641

Property, equipment and software




30,069


26,625


3,769

Operating lease right-of-use assets




16,435


17,592


2,490

Intangible assets




148,844


148,844


21,068

Goodwill




162,574


162,574


23,011

Other non-current assets




18,331


-


-

Total assets




1,737,572


2,048,722


289,979










Liabilities, mezzanine equity and shareholders' equity (deficit)






Current liabilities







Short-term borrowings


50,000


-


-

Accruals and other payables


273,553


243,068


34,404

Operating lease liabilities, current


6,807


8,202


1,161

Ordinary shares to be issued to Everest


258,119


-


-

Total current liabilities




588,479


251,270


35,565

   Convertible promissory notes




68,199


69,138


9,787

Operating lease liabilities, non-current




7,492


7,254


1,027

Deferred subsidy income




3,920


7,760


1,098

Other non-current liabilities




-


9,424


1,334

Total liabilities




668,090


344,846


48,811










Mezzanine equity







Series A convertible preferred shares (US$0.0001 par value,
   30,227,056 shares authorized, issued and outstanding as of
   December 31, 2019, and nil authorized, issued and
   outstanding as of June 30, 2020)

687,482


-


-

Series B convertible preferred shares (US$0.0001 par value,
   30,305,212 shares authorized, issued and outstanding as of
   December 31, 2019, and nil authorized, issued and
   outstanding as of June 30, 2020)

921,243


-


-

Series C convertible preferred shares (US$0.0001 par value,
   31,046,360 shares authorized, issued and outstanding as of
   December 31, 2019, and nil authorized, issued and
   outstanding as of June 30, 2020)

1,306,633


-


-

Series C-1 convertible preferred shares (US$0.0001 par value,
    3,857,143 shares authorized, issued and outstanding as of
    December 31, 2019, and nil authorized, issued and
    outstanding as of June 30, 2020)

188,819


-


-

Total mezzanine equity




3,104,177


-


-

 

 

 

I-MAB
Consolidated Balance Sheets
(All amounts in thousands, except for share and per share data, unless otherwise noted)







As of December 31,


As of June 30,


2019


2020


RMB


RMB


US$ 













Shareholders' equity (deficit)






Ordinary shares (US$0.0001 par value, 500,000,000 and
   800,000,000 shares authorized as of December 31, 2019 and June
   30, 2020, respectively; 8,363,719 and 133,006,644 shares issued
   and outstanding as of December 31, 2019 and June 30, 2020,
   respectively)

6


92


13

Additional paid-in capital

389,379


4,675,991


661,844

Accumulated other comprehensive income

70,127


104,853


14,841

Accumulated deficit

(2,494,207)


(3,077,060)


(435,530)

Total shareholders' equity (deficit)

(2,034,695)


1,703,876


241,168

Total liabilities, mezzanine equity and shareholders' equity 
  (deficit)

1,737,572


2,048,722


289,979

 

 

 

I-MAB

Consolidated Statements of Comprehensive Loss
 (All amounts in thousands, except for share and per share data, unless otherwise noted)



For the six months ended June 30,


2019


2020


RMB


RMB


US$







Revenues






Licensing and collaboration revenue

15,000


-


-







Expenses






Research and development expenses (Note 1)

(265,084)


(442,291)


(62,602)

Administrative expenses (Note 2)

(574,584)


(171,384)


(24,258)

Loss from operations

(824,668)


(613,675)


(86,860)

Interest income

12,818


18,955


2,683

Interest expense

(1,936)


(957)


(135)

Other gains, net

303


12,824


1,815

Fair value change of warrants

(43,854)


-


-

Loss before income tax expense

(857,337)


(582,853)


(82,497)

Income tax expense

-


-


-

Net loss attributable to I-MAB

(857,337)


(582,853)


(82,497)

Net loss attributable to ordinary shareholders

(857,337)


(582,853)


(82,497)







Net loss attributable to I-MAB

(857,337)


(582,853)


(82,497)

Foreign currency translation adjustments, net of nil tax

(4,972)


34,726


4,915

Total comprehensive loss attributable to I-MAB

(862,309)


(548,127)


(77,582)







Net loss attributable to ordinary shareholders

(857,337)


(582,853)


(82,497)

Weighted-average number of ordinary shares used in
   calculating net loss per share - basic and diluted

7,184,086


121,815,986


121,815,986

Net loss per share attributable to ordinary shareholders






?Basic

(119.34)


(4.78)


(0.68)

?Diluted

(119.34)


(4.78)


(0.68)







Note:

(1) Includes share-based compensation expense of RMB308 and RMB132,724 (US$18,786) for the six months ended June 30, 2019 and
2020, respectively.

(2) Includes share-based compensation expense of RMB366,048 and RMB97,071 (US$13,739) for the six months ended June 30, 2019 and
2020, respectively.

 

 

 

I-MAB

Reconciliation of GAAP and Non-GAAP Results

(All amounts in thousands, except for share and per share data, unless otherwise noted)



For the six months ended June 30,



2019


2020



RMB


RMB


US$








GAAP net loss attributable to I-MAB


(857,337)


(582,853)


(82,497)

Add back:







Share-based compensation expense


366,356


229,795


32,525

Non-GAAP adjusted net loss attributable to I-MAB


(490,981)


(353,058)


(49,972)








Non-GAAP adjusted net loss attributable to ordinary
    shareholders


(490,981)


(353,058)


(49,972)

Weighted-average number of ordinary shares used in
   calculating net loss per share - basic and diluted


7,184,086


121,815,986


121,815,986

Non-GAAP adjusted net loss per share attributable to
   ordinary shareholders







?Basic


(68.34)


(2.90)


(0.41)

?Diluted


(68.34)


(2.90)


(0.41)

 

 

SOURCE I-Mab


These press releases may also interest you

at 16:37
Gerber Technology is revolutionizing the flexible materials processing industry with the launch of their end-to-end solution for mass production, which will be unveiled at their annual technology conference, ideation, on November 4-6. The connected...

at 16:35
Oregon Pacific Bancorp (ORPB) today reported financial results for the third quarter ended September 30, 2020. Highlights Third quarter net income of $803 thousand; $0.11 per diluted share Quarterly deposit growth of $20.3 million Quarterly...

at 16:35
The online language learning market is expected to grow by USD 21.57 billion during 2020-2024. The report also provides competitive insights into the market impact and new opportunities created due to the COVID-19 pandemic. According to the latest...

at 16:35
CoreLogic , a leading global provider of property information, insight, analytics and data-enabled solutions, today reported strong operating and financial results for the third quarter ended September 30, 2020 and said it expects full year 2020...

at 16:35
The Conference Planning Services market will register an incremental spend of about USD 52 billion, growing at a CAGR of 3.60% during the five-year forecast period. A targeted strategic approach to Conference Planning Services sourcing can unlock...

at 16:35
The Board of Directors of Holly Energy Partners, L.P. has declared a cash distribution of $0.35 per unit for the third quarter 2020. The distribution will be paid on November 12, 2020 to unitholders of record on November 2, 2020. Holly Energy plans...



News published on 31 august 2020 at 07:00 and distributed by: